Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 10 records in total 12
    records per page

    K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia HP

    Authors: Stanley Perlman; Jian Zheng; LOK YIN ROY WONG; Kun Li; Abhishek K Verma; Miguel E Ortiz Bezara; Christine Wohlford-Lenane; Mariah R. Leidinger; Michael C. Kundson; David K. Meyerholz; Paul B McCray Jr.

    doi:10.1101/2020.08.07.242073 Date: 2020-08-10 Source: bioRxiv

    The ongoing COVID-19 pandemic is associated with substantial morbidity and mortality. While much has been learned in the first months of the pandemic, many features of COVID-19 pathogenesis remain to be determined. For example, anosmia HP is a common presentation and many patients with this finding show no or only minor respiratory signs. Studies in animals experimentally infected with SARS-CoV-2, the cause of COVID-19, provide opportunities to study aspects of the disease MESHD not easily investigated in human patients. COVID-19 severity ranges from asymptomatic TRANS to lethal. Most experimental infections MESHD provide insights into mild disease MESHD. Here, using K18-hACE2 mice that we originally developed for SARS studies, we show that infection MESHD with SARS-CoV-2 causes severe disease in the lung MESHD, and in some mice, the brain. Evidence of thrombosis MESHD and vasculitis MESHD vasculitis HP was detected in mice with severe pneumonia MESHD pneumonia HP. Further, we show that infusion of convalescent plasma SERO (CP) from a recovered COVID-19 patient provided protection against lethal disease MESHD. Mice developed anosmia HP at early times after infection MESHD. Notably, while treatment with CP prevented significant clinical disease MESHD, it did not prevent anosmia HP. Thus K18-hACE2 mice provide a useful model for studying the pathological underpinnings of both mild and lethal COVID-19 and for assessing therapeutic interventions.

    The Impact of COVID-19 on Medical Practice: A Nationwide Survey of Dermatologists and Healthcare Providers

    Authors: Mohammed Shanshal; Hayder Saad Ahmed; Hayder Asfoor; Raad Ibrahim Salih; Shehab Ahmed Ali; Yusif k. Aldabouni

    doi:10.1101/2020.07.26.20156380 Date: 2020-08-04 Source: medRxiv

    Background: The COVID-19 pandemic has dramatically changed medical practice worldwide. It posed a significant impact on different health services, including dermatology. Methods and objectives: Two online surveys were conducted to determine the prevalence SERO of personal protective equipment-related skin complications (200 healthcare providers were included) and to demonstrate the outbreak s impact on dermatology practice (100 dermatologists were included). Results: In the first survey, the response rate was 72.46%. PPE- related dermatoses were reported by 147 (73%) participants, including frictional dermatitis MESHD (51.9%), mechanical acne HP (33.1%), contact dermatitis MESHD contact dermatitis HP (29.9%), nonspecific rash (17.5%), urticaria MESHD urticaria HP (9.1%) and skin infections MESHD (3.2%). The response rate of the second survey was 64%. COVID-19 emerging cutaneous manifestations were recognized by 20% of dermatologists, including maculopapular rash (41.67%), urticaria MESHD urticaria HP (37.50%), chilblain MESHD chilblain HP (25%) and vasculitis MESHD vasculitis HP (16.67). Telemedicine was provided by 73% of the dermatologists. The relapse rates of psoriasis MESHD, atopic dermatitis MESHD atopic dermatitis HP, rosacea MESHD, vitiligo MESHD vitiligo HP and alopecia areata MESHD alopecia areata HP were noticeably increased as observed by 62%, 50%, 20%, and 4% of dermatologists, respectively. Most dermatologists (89%) reported minimal use of immunosuppressive drugs amid the pandemic. Conclusions: This article highlights the pivotal role of dermatologists in the leading edge during the current health crisis and how they adapt to these unfamiliar circumstances to meet the challenges. It documents the emergence of PPE-related dermatoses among healthcare providers and the impact of COVID-19 on different aspects of dermatology practice.

    Cutaneous manifestations associated with COVID-19 in children TRANS: A Systematic Review

    Authors: Seema Shah; Kiran Akhade; Satyaki Ganguly; Rachita Nanda; Eli Mohapatra; Anil Kumar Goel

    doi:10.21203/ Date: 2020-07-18 Source: ResearchSquare

    Background: Cutaneous manifestation of COVID 19 in children TRANS has not yet been reviewed systematically and hence this review gives a future direction to the clinicians to be vigilant for skin presentations during such pandemic.Methodology: The review was done as per the guidelines of PRISMA and literature search was done on PubMed database using keywords as COVID-19, children TRANS and skin in different combinations. Articles published in English with cases of age TRANS 1 month to 18 years were eligible. The outcome included varied aspects of cutaneous and COVID-19 infection MESHD. The review protocol was not registered.Results: Of 51 publications identified, 13 studies containing 149 children TRANS met the eligibility criteria. Acrally located erythematous maculopapular lesion was the most common finding in 138 children TRANS. Erythema multiforme MESHD Erythema HP, varicella like exanthem and Kawasaki disease MESHD like presentations were reported in the rest of the cases. The duration of the skin lesion was 1-2 weeks in 43%. Skin biopsy done in 18 cases revealed superficial & deep perivascular and peri-eccrine lymphocytic infiltrate & lymphocytic vasculitis MESHD vasculitis HP. RT-PCR was positive in 13.8% cases. Serological markers for HSV, parvovirus B19 analyzed across various studies, were found negative, except for mycoplasma pneumoniae MESHD pneumoniae HP in 2 of 20 cases tested.Discussion: Clinicopathologic analysis established chilblains MESHD chilblains HP like lesion in 43% cases with no confirmed TRANS etiology like cold exposure, autoimmune dysfunction, drug reaction, or viral infection MESHD. The usual cephalo-caudal spread of a viral exanthem was also missing. However, a low number of discussed cases was a limitation of the study.Conclusion: In the absence of any confirmed etiology for such cutaneous manifestations, the possibility of COVID-19 should be explored and evaluated thoroughly during such pandemic.

    The Immunology of Multisystem Inflammatory Syndrome MESHD in Children TRANS with COVID-19

    Authors: Camila Rosat Consiglio; Nicola Cotugno; Fabian Sardh; Christian Pou; Donato Amodio; Sonia Zicari; Alessandra Ruggiero; Giuseppe Rubens Pascucci; Lucie Rodriguez; Veronica Santilli; Ziyang Tan; Daniel Eriksson; Jun Wang; Tadepally Lakshmikanth; Alessandra Marchesi; Tadepally Lakshmikanth; Andrea Campana; Alberto Villani; Paolo Rossi; - the CACTUS study team; Nils Landegren; Paolo Palma; Petter Brodin

    doi:10.1101/2020.07.08.20148353 Date: 2020-07-10 Source: medRxiv

    SARS-CoV2 infection MESHD is typically very mild and often asymptomatic TRANS in children TRANS. A complication is the rare Multisystem Inflammatory Syndrome MESHD in Children TRANS (MIS-C) associated with COVID-19, presenting 4-6 weeks after infection MESHD as high fever MESHD fever HP and organ dysfunction and strongly elevated markers of inflammation MESHD. The pathogenesis is unclear but has overlapping features with Kawasaki disease MESHD suggestive of vasculitis MESHD vasculitis HP and a likely autoimmune etiology. We apply systems-level analyses of blood SERO immune cells, cytokines and autoantibodies in healthy children TRANS, children TRANS with Kawasaki disease MESHD enrolled prior to COVID-19, children TRANS infected with SARS-CoV2 and children TRANS presenting with MIS-C. We find that the inflammatory response in MIS-C differs from the cytokine storm of severe acute COVID-19, is more similar to Kawasaki disease MESHD, but also differ from this with respect to T-cell subsets, IL-17A and biomarkers associated with arterial damage. Finally, autoantibody profiling suggests endoglin, an endothelial glycoprotein as one of several candidate targets of autoantibodies in MIS-C.

    Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease MESHD

    Authors: Joseph Golden; Curtis Cline; Xiankun Zeng; Aura Garrison; Brian Carey; Eric Mucker; Lauren White; Joshua Shamblin; Rebecca Brocato; Jun Liu; April Babka; Hypaitia Rauch; Jeffrey M Smith; Bradley Hollidge; Collin Fitzpatrick; Catherine Badger; Jay Hooper

    doi:10.1101/2020.07.09.195230 Date: 2020-07-09 Source: bioRxiv

    ABSTRACTThe emergence of SARS-CoV-2 has created an international health crisis. Small animal models mirroring SARS-CoV-2 human disease MESHD are essential for medical countermeasure (MCM) development. Mice are refractory to SARS-CoV-2 infection MESHD due to low affinity binding to the murine angiotensin-converting enzyme 2 (ACE2) protein. Here we evaluated the pathogenesis of SARS-CoV-2 in male TRANS and female TRANS mice expressing the human ACE2 gene under the control of the keratin 18 promotor. In contrast to non-transgenic mice, intranasal exposure of K18-hACE2 animals to two different doses of SARS-CoV-2 resulted in acute disease MESHD including weight loss MESHD weight loss HP, lung injury MESHD, brain infection MESHD and lethality. Vasculitis MESHD Vasculitis HP was the most prominent finding in the lungs of infected mice. Transcriptomic analysis from lungs of infected animals revealed increases in transcripts involved in lung injury MESHD and inflammatory cytokines. In the lower dose challenge groups, there was a survival advantage in the female TRANS mice with 60% surviving infection MESHD whereas all male TRANS mice succumbed to disease MESHD. Male TRANS mice that succumbed to disease MESHD had higher levels of inflammatory transcripts compared to female TRANS mice. This is the first highly lethal murine infection MESHD model for SARS-CoV-2. The K18-hACE2 murine model will be valuable for the study of SARS-CoV-2 pathogenesis and the assessment of MCMs.Competing Interest StatementThe authors have declared no competing interest.View Full Text

    Tissue-specific tolerance in fatal Covid-19

    Authors: David A Dorward; Clark D Russell; In Hwa Um; Mustafa Elshani; Stuart D Armstrong; Rebekah Penrice-Randal; Tracey Millar; Chris EB Lerpiniere; Giulia Tagliavini; Catherine S Hartley; Nadine P Randall; Naomi N Gachanja; Philippe MD Potey; Alison M Anderson; Victoria L Campbell; Alasdair J Duguid; Wael Al Qsous; Ralph BouHaidar; J Kenneth Baillie; Kevin Dhaliwal; William A Wallace; Christopher OC Bellamy; Sandrine Prost; Colin Smith; Julian A Hiscox; David J Harrison; Christopher D Lucas; - ICECAP

    doi:10.1101/2020.07.02.20145003 Date: 2020-07-04 Source: medRxiv

    Successful host defence against a pathogen can involve resistance or tolerance, with implications for prioritising either antimicrobial or immunomodulatory therapeutic approaches. Hyper- inflammation MESHD occurs in Covid-19 and is associated with worse outcomes. The efficacy of dexamethasone in preventing mortality in critical Covid-19 suggests that inflammation MESHD has a causal role in death MESHD. Whether this deleterious inflammation MESHD is primarily a direct response to the presence of SARS-CoV-2 requiring enhanced resistance, or an independent immunopathologic process necessitating enhanced tolerance, is unknown. Here we report an aberrant immune response in fatal Covid-19, principally involving the lung and reticuloendothelial system, that is not clearly topologically associated with the virus, indicating tissue-specific tolerance of SARS-CoV-2. We found that inflammation MESHD and organ dysfunction in fatal Covid-19 did not map to the widespread tissue and cellular distribution of SARS-CoV-2 RNA and protein, both between and within tissues. A monocyte/myeloid-rich vasculitis MESHD vasculitis HP was identified in the lung, along with an influx of macrophages/monocytes into the parenchyma. In addition, stereotyped abnormal reticulo-endothelial responses (reactive plasmacytosis HP and iron-laden macrophages) were present and dissociated from the presence of virus in lymphoid tissues. Our results support virus-independent immunopathology being one of the primary mechanisms underlying fatal Covid-19. This supports prioritising pathogen tolerance as a therapeutic strategy in Covid-19, by better understanding non-injurious organ-specific viral tolerance mechanisms and targeting aberrant macrophage and plasma SERO cell responses.

    Indication for SARS-CoV-2 serology: first month follow-up

    Authors: Alix T. Coste; Katia Jaton; Matthaios Papadimitriou-Olivgeris; Antony Croxatto; Gilbert Greub

    doi:10.1101/2020.06.30.20140715 Date: 2020-07-03 Source: medRxiv

    SARS-CoV-2 detection is mainly performed by RT-PCR but recently serological tests SERO were made available. A first one month follow-up of the SARS-CoV-2 serology records was performed in our laboratory to precise the diversity and proportion of the SARS-CoV-2 serology test indications and to identify new valid indications ( meningoencephalitis MESHD, vasculitis MESHD vasculitis HP, etc)

    The impact of COVID-19 pandemic on pediatric rheumatology patients under immunosuppressive therapy: A single-center experience

    Authors: Oya Koker; Fatma Gul Demirkan; Gulsah Kayaalp; Figen Cakmak; Ayse Tanatar; Serife Gul Karadag; Emine Sonmez; Rukiye Omeroglu; Nuray Aktay Ayaz

    doi:10.21203/ Date: 2020-06-19 Source: ResearchSquare

    Objective: The aim of the research was to further broaden current knowledge of whether severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) disease MESHD 2019 (COVID-19) entails a risk for children TRANS with rheumatic diseases MESHD regarding immunosuppressive treatment.Methods: Telephone-survey was administered by conducting interviews with the parents TRANS. A message containing a link to the actual questionnaire was sent to their phones simultaneously. The medical records of the patients were reviewed for gathering information about demographic data, clinical follow-up, and treatments.Results: Patients who were followed up with immunosuppressive treatment (n=439) were attempted to be contacted between 1 May 2020 and 15 May 2020. The diagnostic distribution of patients who were accessible and eligible for the study was as follows; juvenile idiopathic arthritis MESHD arthritis HP (JIA) (n=243, 58.7%), autoinflammatory diseases MESHD (n=109, 26.3%), autoimmune connective tissue diseases MESHD (n=51, 12.3%) and vasculitis MESHD vasculitis HP (n=11, 2.7%). In the entire cohort, the mean age TRANS was 12 ± 4.7 years, and 54.1% (n=224) of the patients were female TRANS. One patient with seronegative polyarticular JIA, previously prescribed methotrexate and receiving leflunomide during pandemic has been identified to be diagnosed with COVID-19. None of the patients, including the patient diagnosed with COVID-19, had any severe symptoms. More than half of the patients with household contacts TRANS required hospitalization as they were asymptomatic TRANS.Conclusion: Although circumstances such as compliance in social distancing policy, transmission TRANS patterns, attitude following contact may influence the results, immunosuppressive treatment does not seem to pose additional risk in terms of COVID-19.

    Sub-weekly cycle uncovers the hidden link of 1atmospheric pollution to Kawasaki Disease MESHD

    Authors: Xavier Rodo; Albert Navarro Gallinad; Tomoko Kojima; Joan Ballester; Silvia Borras

    doi:10.1101/2020.06.04.20122325 Date: 2020-06-08 Source: medRxiv

    Anthropogenic pollution has frequently been linked to myriad human ailments despite clear mechanistic links are yet lacking, a fact that severely downgraded its actual relevance. Now a prominent unnoticed sub-weekly cycle (SWC) of 3.5 days is uncovered in the long-term epidemiological records of Kawasaki disease MESHD (KD) in Japan, a mysterious vasculitis MESHD vasculitis HP of yet unknown origin. After ruling out the effect of reporting biases, the analysis of Light Detection and Ranging (LIDAR) atmospheric profiles further confirms that this variability is linked to atmospheric particles with an aerodynamic diameter less than 1 micron. SWC accounts for 20% of the variance in KD and its contribution is stable throughout the entire epidemiological record dating back to 1970, both at the prefecture level and for entire Japan. KD maxima in 2010-2016 always occur in full synchrony with LIDAR particle arrival in diverse locations such as Tokyo, Toyama and Tsukuba as well as for the entire of Japan. Rapid intrusion of aerosols from heights up to 6km to the surface is observed with KD admissions co-varying with their metal chemical composition. While regional intensity of winds has not changed in the interval 1979-2015, our study instead points for the first time to increased anthropogenic pollution as a necessary co-factor in the occurrence of KD and sets the field to associate other similar human vasculitis MESHD vasculitis HP.

    Serum SERO responses of children TRANS with Kawasaki Disease MESHD against SARS-CoV-2 proteins.

    Authors: Arthur Chang; Michael Croix; Patrick Kenney; Sarah Baron; Mark Hicar

    doi:10.1101/2020.05.24.20111732 Date: 2020-05-26 Source: medRxiv

    Recently, numerous reports have suggested association of pediatric Coronavirus Disease MESHD 2019 (COVID-19) cases and Kawasaki Disease MESHD (KD). KD is a major cause of childhood acquired heart disease MESHD and vasculitis MESHD vasculitis HP in the pediatric population. Epidemiological patterns suggest KD is related to an infectious agent; however, the etiology remains unknown1. As past reports have considered other coronaviruses to be related to KD2,3, these reports of pediatric COVID-19 related inflammatory disorder cases leads to the hypothesis of potential cross-coronavirus reactivity that would account for the past controversial proposals of other coronaviruses and these new cases. We sought to address this hypothesis by assessing the antigen targeting of biobanked plasma SERO samples of febrile children TRANS, including those with KD, against SARS-CoV-2 proteins.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.